Your browser doesn't support javascript.
loading
Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.
Fuerst, Rita; Yong Choi, Jun; Knapinska, Anna M; Smith, Lyndsay; Cameron, Michael D; Ruiz, Claudia; Fields, Gregg B; Roush, William R.
Afiliação
  • Fuerst R; Department of Chemistry, Scripps Florida, Jupiter, FL 33458, United States; Institute of Organic Chemistry, Graz University of Technology, 8010 Graz, Austria.
  • Yong Choi J; Department of Chemistry, Scripps Florida, Jupiter, FL 33458, United States; Department of Chemistry and Biochemistry, Queens College and the Graduate Center of the City University of New York, New York 11367, United States.
  • Knapinska AM; Department of Chemistry & Biochemistry, Florida Atlantic University, Jupiter, FL 33458, United States.
  • Smith L; Department of Chemistry & Biochemistry, Florida Atlantic University, Jupiter, FL 33458, United States.
  • Cameron MD; Department of Chemistry, Scripps Florida, Jupiter, FL 33458, United States.
  • Ruiz C; Department of Chemistry, Scripps Florida, Jupiter, FL 33458, United States.
  • Fields GB; Department of Chemistry & Biochemistry, Florida Atlantic University, Jupiter, FL 33458, United States.
  • Roush WR; Department of Chemistry, Scripps Florida, Jupiter, FL 33458, United States. Electronic address: roush@scripps.edu.
Bioorg Med Chem ; 26(18): 4984-4995, 2018 10 01.
Article em En | MEDLINE | ID: mdl-30249495
ABSTRACT
A structure-activity/structure-property relationship study based on the physicochemical as well as in vitro pharmacokinetic properties of a first generation matrix metalloproteinase (MMP)-13 inhibitor (2) was undertaken. After systematic variation of inhibitor 2, compound 31 was identified which exhibited microsomal half-life higher than 20 min, kinetic solubility higher than 20 µM, and a permeability coefficient greater than 20 × 10-6 cm/s. Compound 31 also showed excellent in vivo PK properties after IV dosing (Cmax = 56.8 µM, T1/2 (plasma) = 3.0 h, Cl = 0.23 mL/min/kg) and thus is a suitable candidate for in vivo efficacy studies in an OA animal model.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Metaloproteinase 13 da Matriz / Inibidores de Metaloproteinases de Matriz Limite: Animals / Humans Idioma: En Revista: Bioorg Med Chem Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Metaloproteinase 13 da Matriz / Inibidores de Metaloproteinases de Matriz Limite: Animals / Humans Idioma: En Revista: Bioorg Med Chem Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Áustria